Legal & General Group’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Legal & General Group’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-5,685	Closed	-$52K	–	3473
2017 Q1	$52K	Sell	5,685 -99	-2%	-$869	﹤0.01%	2861
2016 Q4	$44K	Buy	5,784 +3,367	+139%	+$30.9K	﹤0.01%	2920
2016 Q3	$27K	Hold	2,417	–	–	﹤0.01%	2769
2016 Q2	$29K	Hold	2,417	–	–	﹤0.01%	2765
2016 Q1	$24K	Hold	2,417	–	–	﹤0.01%	2645
2015 Q4	$53K	Hold	2,417	–	–	﹤0.01%	2437
2015 Q3	$36K	Hold	2,417	–	–	﹤0.01%	2602
2015 Q2	$54K	Hold	2,417	–	–	﹤0.01%	2510
2015 Q1	$63K	Hold	2,417	–	–	﹤0.01%	2372
2014 Q4	$52K	Hold	2,417	–	–	﹤0.01%	2423
2014 Q3	$46K	Buy	+2,417	New	+$48.6K	﹤0.01%	2442

Other funds holding OMED

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

IHM

Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Legal & General Group's OMED Position: Q2 2017 in Review

Legal & General Group sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2017, closing a stake of 5,685 shares — an estimated $52K sold.

Legal & General Group first reported a position in OMED in Q3 2014 and held it in 11 quarters. The position peaked at $63K in Q1 2015. 68 funds tracked by Wall St. Rank hold OMED as of Q2 2017.

Legal & General Group reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Legal & General Group sold 5,685 OncoMed Pharmaceuticals, Inc. shares in Q2 2017, an estimated $52K.
Legal & General Group first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2014 and held it in 11 quarters.
Legal & General Group's OncoMed Pharmaceuticals, Inc. position peaked at $63K in Q1 2015.
68 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2017.

Based on Legal & General Group's 13F filing for Q2 2017, filed 3 Aug 2017.